tbuckley/cabot-search huggingface dataset:
Abstract 19329: Impact of Dipyridamole on Adenosine Dosing in Pediatric and Young Adult Patients After Heart Transplant
Authors: Michael B Satzer, Jonathan N Flyer, Warren A Zuckerman, Leonardo Liberman, Marc E Richmond, Brett R Anderson, Linda J Addonizio, Eric S Silver
Journal: Circulation (2017)

Introduction:  Adenosine as an antiarrhythmic agent has been relatively contraindicated following heart transplant. Dipyridamole, often prescribed after transplant, is thought to potentiate adenosine. Adult guidelines recommend lower adenosine doses in patients on dipyridamole, based on limited evidence. In an initial prospective study, we demonstrated safety and efficacy of adenosine to induce atrioventricular (AV) block in pediatric and young adult patients; 42 patients were on dipyridamole, suspended ≥ 72 hours before testing. Safety and efficacy on dipyridamole is unknown.   Methods:  In a prospective follow-up study, we reassessed safety and efficacy of adenosine in healthy young patients after heart transplant on dipyridamole (4/2016 - 6/2017). Patients were eligible if they took part in the parent study, were on dipyridamole and returned for routine cardiac catheterization (39 patients). After cardiac biopsy, we placed a temporary ventricular pacing wire and dosed adenosine in stepwise increments until ≥ 1 P wave was blocked or max dose reached (200mcg/kg or 12mg). The primary outcome was clinically significant asystole (≥ 12 seconds). Secondary outcomes included the lowest adenosine dose causing AV block, block duration, cardiac ectopy and patient reported symptoms. Incidence and 95% confidence intervals for categorical outcomes were calculated. Paired outcomes from the current and parent study were compared.   Results:  Thirty patients (5 - 24 years) were tested. No patient (0%, CI 0 - 8%) experienced significant asystole. AV block occurred in 29 patients (97%, CI 86 - 100%). Seventeen patients (57%, CI 39 - 72%) required less adenosine to achieve AV block on dipyridamole; six (20%) required more. The median lowest dose causing AV block was 50mcg/kg (vs. 100mcg/kg off dipyridamole; P=0.013). No block occurred    Conclusion:  AV block occurs often at half the dose of adenosine in healthy pediatric and young patients after transplant on oral dipyridamole. Initial dosing of 25mcg/kg (max 0.8mg) with stepwise escalation poses low risk.
P2.07-012 Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
Authors: S. Schmid, S. Diem, M. Krapf, Q. Li, L. Flatz, S. Leschka, L. Desbiolles, D. Klingbiel, W. Jochum, M. Früh
Journal: Journal of Thoracic Oncology (2017)
P1.03-009 Venous Thromboembolism (VTE) in Lung Cancer - Associations and Prognostic Role: Results of a Prospective Cohort Study from North India
Authors: R Lakshmi Narasimhan, Navneet Singh, Mandeep Garg, Jasmina Ahluwalia, Digambar Behera
Journal: Journal of Thoracic Oncology (2017)
Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation
Authors: Stijn E. Verleden, Bart M. Vanaudenaerde, Marie-Paul Emonds, Dirk E. Van Raemdonck, Arne P. Neyrinck, Geert M. Verleden, Robin Vos
Journal: European Respiratory Journal (2017)

Donor-specific antibodies (DSAs) against human leukocyte antigen (HLA) are associated with chronic lung allograft dysfunction (CLAD) and mortality post lung transplantation, but data concerning prevalence, time of onset, persistence and effects on long-term outcome remain scarce. We assessed the association between HLA antibodies and CLAD-free and graft survival in a cohort of 362 patients. We stratified our analysis according to DSA status, persistence of antibodies and timing of antibodies (pre-transplant, early or late post-transplant). Within our cohort, 61 (17%) patients developed DSAs (mostly against HLA-DQ), which was associated with worse CLAD-free and graft survival (p&lt;0.0001 and p=0.059, respectively). Persistent (hazard ratio (HR) 3.386, 95% CI 1.928–5.948; p&lt;0.0001) as well as transient (HR 2.998, 95% CI 1.406–6.393; p=0.0045) DSAs were associated with shorter CLAD-free survival compared with patients without DSAs. Persistent DSAs (HR 3.071, 95% CI 1.632–5.778; p=0.0005) but not transient DSAs were negatively associated with graft survival compared with patients without DSAs, likely due to the higher incidence of restrictive CLAD. HLA non-DSAs and pre-transplant HLA antibodies had no effect on post-transplant outcome. We demonstrated an important difference in prognosis between persistent and transient DSAs. Moreover, the observed association between DSAs and restrictive CLAD suggests an overlap between antibody-mediated rejection and restrictive CLAD that needs further investigation.
Use of Atrial Strain to Predict Atrial Fibrillation After Cerebral Ischemia
Authors: Faraz Pathan, Eswar Sivaraj, Kazuaki Negishi, Rifly Rafiudeen, Shahab Pathan, Nicholas D’Elia, John Galligan, Samuel Neilson, Ricardo Fonseca, Thomas H. Marwick
Journal: JACC. Cardiovascular imaging (2017)
Frequency of L858R and L861Q EGFR mutation in triple-negative, luminal and HER2 of Indonesian breast cancers patients
Authors: D. Budhiarko, T.P. Putra, A.T. Harsono, N. Masykura, D. Tjindarbumi, G. Widjajahakim, A. Utomo
Journal: Annals of Oncology (2017)
A phase I pharmacokinetic study of metronomic vinorelbine and sorafenib using two schedules in Asian non-small cell lung cancer (NSCLC) patients
Authors: S. Chen, N. Sutiman, V. Shih, D. Tan, M.K. Ang, C.K. Toh, D. Lim, Q.S. Ng, E.H. Tan, B. Chowbay
Journal: Annals of Oncology (2017)
PS03.01 Elective Nodal Irradiation for Limited-Stage Small Cell Lung Cancer: A survey of US Radiation Oncologists on Practices
Authors: M.J. Farrell, J. Yahya, C. Degnin, Y. Chen, J.M. Holland, M.A. Henderson, J.J. Jaboin, M.M. Harkenrider, C.R. Thomas, T. Mitin
Journal: Journal of Thoracic Oncology (2017)
Scientists wake up to coffee’s benefits
Authors: Anne Gulland
Journal: BMJ (2017)

Drinking three to four cups of coffee a day is associated with health benefits across a range of diseases and conditions. A review published in The BMJ this week identified 201 meta-analyses of observational research and 17 meta-analyses of interventional research and found that coffee consumption was more often associated with benefit than harm over various health outcomes.1

The researchers found that drinking three cups of coffee a day was associated with the greatest benefit in terms of cardiovascular disease, coronary heart disease, and stroke, when compared with not drinking coffee. Consumption at this level was associated with a 19% lower risk of mortality from cardiovascular disease (relative risk 0.81, 95% confidence interval 0.72 to 0.90), a 16% lower risk of mortality from coronary heart disease (relative risk 0.84, 0.71 to 0.99), and a 30% lower risk of stroke mortality (0.70, 0.80 to 0.90). Increasing consumption to more than three cups a day was …
Abstract P244: MicroRNAs Implicated in Angiogenesis Are Upregulated in Lower Extremity Peripheral Artery Disease (PAD): the San Diego Population Study (SDPS)
Authors: Christina Wassel, Jane E Freedman, Kahraman Tanriverdi, Peter Durda, Russell P Tracy, Matthew A Allison, Joachim H Ix, Julie O Denenberg, Michael H Criqui
Journal: Circulation (2017)

Introduction: Lower extremity PAD affects approximately 9 million people in the US. However, the genetic factors underlying PAD remain elusive. MicroRNAs are short non-coding RNA segments that regulate gene expression post-transcriptionally. MicroRNAs are hypothesized to be involved in angiogenesis, inflammation, and immune processes central to atherosclerotic process, are modifiable, and thus have potential as therapeutic targets. No previous studies have assessed the role of microRNAs in PAD in a population-based sample. Methods: The SDPS is a prospective population-based cohort of non-Hispanic White, African-American, Hispanic and Asian men and women designed to study PAD and venous disease. A sex- and age-matched nested sample of 24 PAD cases and 24 controls were chosen from 1103 participants who attended the 2007-11 exam. PAD was defined as ankle brachial index (ABI)&lt;0.90, while the ABI range for controls was 1.1-1.3. Thirty-five microRNAs hypothesized to be of importance in development of atherosclerosis were measured in plasma using a high throughput RT qPCR method on the BioMark microfluidic System. MicroRNA expression levels (Cq values) were compared between PAD cases and controls using linear regression and least squares means, with adjustment for age and sex to remove residual confounding. Results: Overall mean±SD age was 79±7, with mean ABI among the PAD cases of 0.60±0.12 and among controls was 1.17±0.06.Six microRNAs, miR-181b, -195, -22, -27b, -424, and -503, were significantly upregulated in PAD cases vs. controls ( Figure ), all p&lt;0.05. Existing evidence indicates that miR-195,-27b, -424, and -503 are involved in angiogenesis, and miR-503 is upregulated in ischemic leg muscle of patients with diabetes. Conclusions: Individuals with PAD have significantly higher expression of miRNAs linked to angiogenesis.Additional research is needed in larger studies to further assess associations with clinical and subclinical PAD, as well as the viability of these miRNAs as therapeutic targets for PAD.
Development of a serious illness care model implementation framework.
Authors: Khue Nguyen, Theresa Schmidt, Sibel Ozcelik, Janice Bell, Robin L. Whitney
Journal: Journal of Clinical Oncology (2017)

161 Background: Care of individuals with cancer and other serious illness is complex and often results in unmet needs and high costs. Despite growing national interest in innovative care models for serious illness that improve quality and reduce costs, limited information is available to guide health care organizations from program innovation to implementation. Methods: With funding from the Gordon and Betty Moore Foundation, we sought to develop a flexible serious illness care model implementation framework to inform program development, replication, and scaling across a broad range of serious illness populations and settings. A draft framework was developed, guided by review of white papers and peer reviewed evidence and of existing serious illness care programs. Expert panelists—representative of serious illness care providers, policy experts, payers, and researchers—were recruited to review and provide feedback in two rounds of group discussion and additional 1:1 interviews. Results: The resulting framework implementation process begins with setting a vision and completing a local needs assessment. We present a range of evidence-based options for each facet of care model implementation (e.g., possible business models, target populations, services, and outcomes) to guide healthcare organizations in adapting serious illness programs to their local context. Key considerations for encouraging program success include leveraging existing programs and resources, recruiting strong program leaders, engaging staff, assembling experienced multidisciplinary care teams, building strong relationships among team members and with patients/caregivers, and establishing processes for program evaluation and continuous quality improvement. Conclusions: Our framework reflects a growing landscape of care models for cancer and other serious illness, offering a range of potential approaches to program implementation. Next steps include dissemination, framework impact assessment, creating a simulator for payment models, and piloting framework for use with future programs.
Progestin-associated shift of meningioma mutational landscape
Authors: M. Peyre, S. Gaillard, C. de Marcellus, M. Giry, F. Bielle, C. Villa, A.L. Boch, H. Loiseau, B. Baussart, L. Cazabat, M.L. Raffin-Sanson, M. Sanson, M. Kalamarides
Journal: Annals of Oncology (2017)
Off-label drug use in home palliative care: A non-evidence-based established practice.
Authors: Laura Velutti, Carlotta Pavesi, Diego Lopane, Concetta Arcanà, Annalisa Saetta, Ana Paula De Maio, Tatiana Speciale, Lorenza Rimassa, Armando Santoro
Journal: Journal of Clinical Oncology (2017)

225 Background: Advanced cancer patients (pts) often present with multiple concomitant symptoms and off-label use of drugs (indications doses formulations administration route) is a common practice. Drugs mixture (DM) solutions by continuous administration are frequently used. However, evidence-based data in this setting is scarce. Methods: We performed a retrospective analysis of 576 consecutive care pathways provided by our Home Palliative Care (HC) Service from Jul 2010 to Jun 2017. Infusions were administered subcutaneously (sc) or by a venous (iv) access, by elastomeric pumps (EP) (5 days - 2 mL/h) with drugs diluted in 0.9% NaCl with no light protection. We analyzed: treated symptoms, drugs, doses/concentrations, solution transparency, administration route, infusion duration, clinical response, adverse events (AEs), compliance/treatment acceptability, device proper functioning, and treatment interruptions. Results: We analyzed 266 pts out of 576 care pathways treated with DM infusions, M/F 143/123, median age 70 yrs (21-92); treated symptoms: pain (50%), nausea/vomiting (20%), dyspnea/agitation (20%), dysphagia/mucositis (18%); infused drugs: morphine, midazolam, dexamethasone, ranitidine, metoclopramide, scopolamine, alizapride, haloperidol, furosemide, and ketorolac. Median number of drugs in the DM was 3 (1-6). Administration route was sc in 214 pts/80%, iv in 52 pts/20%. Median infusion duration was 5 days (0-64). Symptoms control was achieved within 72 h in 69% of pts. No AEs related to the infusion devices were observed. Compliance was good in 92% of pts, poor/inadequate in 8%. 5 EP malfunctions were observed: 1 human error, 1 device obstruction due to furosemide flocculation, 3 unexplained. Also, 3 pts required sc infusion interruption due to fluid accumulation near the injection site. Conclusions: This retrospective analysis on a large number of pts shows efficacy and tolerability of DM administration by EP in the HC setting. Treatment compliance was high, no AEs were observed, EP malfunction and therapy discontinuation were rare. However, there are still many open questions about the off-label use of drugs in this setting, and prospective trials are strongly suggested.
Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome
Authors: Y. Nakamura-Nishimura, F. Miyagawa, K. Miyashita, R. Ommori, H. Azukizawa, H. Asada
Journal: British Journal of Dermatology (2017)

Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DIHS) is a severe adverse drug-induced reaction with reactivation of human herpesvirus 6 (HHV-6).1-3 We previously reported that serum thymus and activation-regulated chemokine (TARC) levels were markedly increased in patients with DIHS and suggested TARC as a useful diagnostic marker of DIHS in the early stage.4,5 In this study, we determined whether serum TARC levels correlate with the severity of clinical symptoms and laboratory data in patients with DRESS/DIHS.

This article is protected by copyright. All rights reserved.
A PIP <sub>2</sub> -derived amplification loop fuels the sustained initiation of B cell activation
Authors: Chenguang Xu, Hengyi Xie, Xingdong Guo, Haipeng Gong, Lei Liu, Hai Qi, Chenqi Xu, Wanli Liu
Journal: Science Immunology (2017)

A PIP 2 -derived amplification loop fuels the sustained initiation of B cell activation.
P3.02b-036 The Predictive Factors for Post-Progression Survival after EGFR-TKI Failure in Advanced EGFR-Mutant Lung Cancer Patients
Authors: Toshiki Ebisudani, Kei Nakashima, Masafumi Misawa, Akiko Tokumoto, Masahiro Nemoto, Ryuta Tsuzuki, Fumi Suzuki, Satoshi Yamawaki, Ayumu Otsuki, Satoshi Noma, Masahiro Aoshima
Journal: Journal of Thoracic Oncology (2017)
The outcome of outpatient palliative care service at Yonsei Cancer Center, a tertiary cancer center in Korea.
Authors: Si Won Lee, Hye Jin Choi
Journal: Journal of Clinical Oncology (2017)

131 Background: The importance of palliative care in cancer patients continues to be emphasized and studies are proving its importance. Several studies proved the improvement of quality of life in advanced cancer patients. The efficacy of symptom control based on outpatient palliative care service has not yet been reported in Korea. The objective of this study is to review the outcome of outpatient palliative care service at Yonsei Cancer Center, a tertiary cancer center in Korea. Methods: We retrospectively reviewed 155 cancer patients who used outpatient clinic at Yonsei Cancer Center in Korea between April 2014 and December 2014. Symptom severity was measured by modified Korean version of Edmonton Symptom Assessment System. Twelve symptoms were assessed: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, sleep disorder, anorexia, constipation, wellbeing, financial distress. Higher score means worse symptom. ESAS scores at baseline and follow-up assessments were analyzed. Results: The 155 patients had following characteristics: female 52.3%, median age 65 years (range 58-75), Hepatobiliary-pancreatic cancer and lung cancer patients accounted for the largest portion (n = 37, 23.9%; n = 36, 23.2% respectively). Most patients were Eastern Cooperative Oncology Group performance status 1 (n = 28, 18.1%) or 2 (n = 24, 15.5%). Ninety-two (59.4%) patients were referred to the palliative care team after anti-cancer treatments were all finished. Overall the symptoms did not change significantly from baseline to 2 consecutive follow up assessment except anorexia ( p value = 0.0195). Patients who were on active anticancer treatment had tendency of higher ESAS score than those finished with the anticancer treatment. However, all symptoms except nausea were not statistically significant. Conclusions: Most patients in this study did not have severe symptom scores that would show the differences of the symptom changes. Nevertheless, although not statistically significant, we found that patients on active anticancer treatment had higher symptom burden than those who were finished with the anticancer treatment. More meticulous symptom management is necessary to improve the symptom control.
La nueva variante de la enfermedad de Creutzfeldt-Jakob
Authors: D Dormont
Journal: Eurosurveillance (2000)

Los trabajos de patologia experimental realizados desde hace mas de 10 anos indican que las propiedades biologicas del agente de la EEB, causante de la nueva variante de la enfermedad de Creutzfeldt-Jakob (nvECJ), son muy especificas. A diferencia de lo observado en la forma clasica de ECJ, la localizacion del agente responsable de la nvECJ en el hombre es, en gran medida, periferica. Esto exige un replanteamiento de la seguridad ofrecida por los transplantes, los farmacos de origen humano o bovino y las transfusiones.
Paving the Way for Targeted Drug Development in Schizophrenia
Authors: Nina Vanessa Kraguljac, Adrienne Carol Lahti
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract 12501: Abnormal Activation of TGFβ Signaling as a Pathogenesis of Left Ventricular Non-compaction Cardiomyopathy
Authors: Kazuki Kodo, Sang-Ging Ong, Fereshteh Jahanbani, Vittavat Termglinchan, Hirono Keiichi, Kolsoum InanlooRahatloo, Antje D Ebert, Praveen Shukla, Oscar J Abilez, Jared M Churko, Ioannis Karakikes, Gwanghyun Jung, Fukiko Ichida, Michael P Snyder, Daniel Bernstein, Joseph C Wu
Journal: Circulation (2015)

Left ventricular non-compaction (LVNC) is the third most prevalent cardiomyopathy in children and has a unique phenotype with characteristically extensive hypertrabeculation of the left ventricle, similar to the embryonic left ventricle, suggesting a developmental defect of the embryonic myocardium. However, in-depth investigation of this disease has been challenging due to the lack of animal models that can faithfully recapitulate the clinical phenotype of LVNC. In this study, we demonstrated that patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) generated from LVNC patients carrying a mutation in cardiac transcription factor TBX20 recapitulated a developmental defect consistent with the LVNC phenotype at the single-cell level. We first performed genetic tests and identified two TBX20 mutations, Y317* and T262M from multiple members in a family with LVNC history and one isolated patient. We then utilized iPSC-CMs to show that increased transforming growth factor beta (TGFβ) signaling is one of the central mechanisms underlying the pathogenesis of LVNC caused by TBX20 mutation. LVNC iPSC-CMs demonstrated decreased proliferative capacity due to abnormal activation of TGFβ signaling (Figs. A-B). TBX20 regulated the expression of TGFβ signaling modifiers including ITGAV and the Smad cofactor, PRDM16, which is a known genetic cause of LVNC. Genome editing of PRDM16 in control iPSC-CMs led to proliferation defects as seen in LVNC iPSC-CMs. Inhibition of abnormal TGFβ signaling by TGFβ receptor-1 inhibitors or ITGAV inhibitor, or genetic correction of the TBX20 mutation using TALEN reversed the proliferation defects seen in LVNC iPSC-CMs (Figs. C-D). Our results demonstrate that iPSC-CMs are a useful tool for the exploration of novel mechanisms underlying poorly understood cardiomyopathies such as LVNC. Here we provide the first evidence of activation of TGFβ signaling as playing a role in the pathogenesis of LVNC.
Vigilância sentinela da gripe na Europa, 1997/1998
Authors: M Zambon
Journal: Eurosurveillance (1998)

A circulacao do virus da gripe esta associada com o aumento da taxa de consultas dos clinicos gerais (CG) (1), aumento das admissoes hospitalares (2) e excesso de mortes (3) e tem de ser considerada no planeamento dos cuidados de saude. Na Europa Ocidental, normalmente os virus da gripe circulam nos meses de Inverno, geralmente entre Outubro e Marco. Durante esta estacao, a vigilância clinica da doenca respiratoria e intensificada em varios paises europeus.
Causal generative models are just a start
Authors: Ernest Davis, Gary Marcus
Journal: Behavioral and Brain Sciences (2017)

Abstract Human reasoning is richer than Lake et al. acknowledge, and the emphasis on theories of how images and scenes are synthesized is misleading. For example, the world knowledge used in vision presumably involves a combination of geometric, physical, and other knowledge, rather than just a causal theory of how the image was produced. In physical reasoning, a model can be a set of constraints rather than a physics engine. In intuitive psychology, many inferences proceed without detailed causal generative models. How humans reliably perform such inferences, often in the face of radically incomplete information, remains a mystery.